Exercise of Options

RNS Number : 5095T

Ergomed plc

25 November 2021

 

 PRESS RELEASE

Exercise of Share Options and Total Voting Rights

Guildford, UK - 25 November 2021: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, following an exercise of share options, application has been made to AIM for the admission of 11,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").

Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 26 November 2021.  Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following Admission on 26 November 2021, the total number of ordinary shares with voting rights in issue will be 49,132,071. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited (Nominated Adviser and Joint Broker)	Tel: [phone]
Freddie Barnfield / Matthew O'Dowd
James Black (Broker) Peel Hunt LLP (Joint Broker)   James Steel / Dr Christopher Golden	Tel: [phone]
Consilium Strategic Communications	Tel: [phone]
Chris Gardner / Matthew Neal	[e-mail]
Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

 

END

 

 

MSCBIBRTMTMTBBB